Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review

Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review

BackgroundPatients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of p...

Full description

Bibliographic Details
Main Authors: Jiayi Li, Xin Zhang, Zhuanzhuan Mu, Di Sun, Yuqing Sun, Yansong Lin
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Immunology
Subjects:
radioactive iodine refractory
differentiated thyroid cancer
combination immunotherapy
multitargeted kinase inhibitors plus PD-1/PD-L1 inhibitors therapy
apatinib plus camrelizumab treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.943916/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.943916/full

Similar Items